Xeris Pharmaceuticals announces a limited time $0 Copay for GvokeTM PFS for People With Diabetes. This will be available for commercially eligible patients effective now through April 30, 2020 as a response to the COVID-19 pandemic.
Xeris pharmaceuticals wants people with diabetes to be able to easily inject prefilled and premixed glucagon in the case of a severe low without the stress of financial barriers. The $0 copay card is available to commercially insured patients, who may or may not have Gvoke covered by their insurance plan. If a prior authorization is required, the $0 copay offer can be applied to the prescription.
Gvoke is a great option for glucagon since it is ready to use and no steps are required to prepare for the injection. Loved ones can easily administer to a person with diabetes in severe and urgent situations. This is a great offer they have made for people that might have had to pay out of pocket for this potential life saving tool during a difficult time.
To access a digital copay card, visit: https://www.gvokeglucagon.com/savings-and-support
For more information visit: https://www.biospace.com/article/releases/xeris-pharmaceuticals-announces-0-copay-for-gvoke-pfs-for-people-with-diabetes/
Back to April 2020 Newsletter
